| 摘要 |
The presently disclosed subject matter provides a dosing regimen and administration schedule for the use of 1-deoxygalactonojirimycin and enzyme replacement therapy for the treatment of Fabry disease. The presently disclosed 5 subject matter further provides a dosing regimen and administration schedule for the use of migalastat hydrochloride and agalsidase for the treatment of Fabry disease. Period = ERT Alone -0- 2001-003, 1.0 mg/kg + 2017-001, 0.5 mg/kg +-2018-001, 0.5 mg/kg 3500 -A- 2018-002, 1.0 mg/kg 3000- -- 2018-003, 0.5 mg/kg 2500- + 2018-004, 0.5 mg/kg 0 E 0 2 4 6 8 10 12 14 16 18 20 22 24 Time (hr) Period = Co-Administration -0- 2001-003, 1.0 mg/kg+AT1001 150 mg E + 2017-001, 0.5 mg/kg+AT1001 150 mg +02018-001, 0.5 mg/kg+AT1001 150 mg 3500- -A- 2018-002, 1.0 mg/kg+AT1001 150 mg 3000-2018-003, 0.5 mg/kg+AT1001 150 mg 2500- + 2018-004, 0.5 mg/kg+AT1001 150 mg 0 E 0 2 4 6 8 10 12 14 16 18 20 22 24 Time (hr) |
